Maryland Life Sciences, a division of the Maryland Tech Council, is pleased to announce that Peter Marks, Ph.D., Director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration (FDA), will serve as keynote speaker at the 2023 Bio Innovation Conference on Monday, October 30, 2023 at the Bethesda North Marriot and Conference Center.
Under Dr Peter Marks’ leadership, CBER is responsible for assuring the safety and effectiveness of biological products, including vaccines, allergenic products, blood and blood products, and cellular, tissue, and gene therapies. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016.
Dr Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University. He completed an Internal Medicine residency and Hematology/Medical Oncology fellowship at Brigham and Women’s Hospital in Boston, where he subsequently joined the attending staff as a clinician-scientist and eventually served as Clinical Director of Hematology.
He served in the pharmaceutical industry on the clinical development of hematology and oncology products prior to returning to academic medicine at Yale University where he led the Adult Leukemia Service and served as Chief Clinical Officer of Smilow Cancer Hospital.
Dr. Marks is board certified in internal medicine, hematology and medical oncology, and is a Fellow of the American College of Physicians. In 2022, he became a Member of the National Academy of Medicine, one of the highest honors in the fields of health, science and medicine.
“Dr Peter Marks has been at the forefront of cell and gene therapy advances for more than a decade,” said Kelly Schulz, CEO of the Maryland Tech Council. “Bio Innovation Conference attendees will be fortunate to hear Dr. Marks’ unique insights into the future of cell and gene therapy and how to make them a reality for patients around the world.”
“Maryland is rapidly becoming an important hub for cell and gene therapy manufacturing,” said Brad Stewart, Chair of Maryland Life Sciences. “We are excited to have a speaker of Dr. Marks’ caliber explore the promise of cell and therapies as well as the critical role that advanced manufacturing has in scaling up the therapies for patients in need.”